Member Login | New USER
Florida Hospital Association
  • Advocacy
    • State Advocacy
    • Federal Advocacy >
      • Letters
    • FHA Political Committee
  • Health Care Issues
    • Behavioral Health
    • Workforce >
      • Workforce Resources
    • Patients Awaiting Discharge to Post-Acute Care Settings
    • Emergency Management
    • Accreditation
    • Compliance/HIPAA
    • Hospital Finances
    • Quality & Safety
  • Education & Events
    • Calendar
    • Popular Education Series >
      • Novice Infection Prevention Series
      • Statewide Readmissions Prevention Series
    • Sponsor Opportunities
  • Reports & Resources
    • Facts and Stats
    • Florida Nurse Workforce Projections - 2035
    • Understanding Your Hospital Bill
    • Guidance Documents
    • Medicare 101 Manual
    • Compliance Standards Manual
    • Florida HIPAA Preemption Analysis
  • News
  • About Us
    • Our Team
    • Board of Trustees
    • Member Directory
  • Advocacy
    • State Advocacy
    • Federal Advocacy >
      • Letters
    • FHA Political Committee
  • Health Care Issues
    • Behavioral Health
    • Workforce >
      • Workforce Resources
    • Patients Awaiting Discharge to Post-Acute Care Settings
    • Emergency Management
    • Accreditation
    • Compliance/HIPAA
    • Hospital Finances
    • Quality & Safety
  • Education & Events
    • Calendar
    • Popular Education Series >
      • Novice Infection Prevention Series
      • Statewide Readmissions Prevention Series
    • Sponsor Opportunities
  • Reports & Resources
    • Facts and Stats
    • Florida Nurse Workforce Projections - 2035
    • Understanding Your Hospital Bill
    • Guidance Documents
    • Medicare 101 Manual
    • Compliance Standards Manual
    • Florida HIPAA Preemption Analysis
  • News
  • About Us
    • Our Team
    • Board of Trustees
    • Member Directory
Important Updates Regarding the FDA Emergency Use Authorization for Monoclonal Antibody Cocktail - Casirivimab and Imdevimab
July 28, 2021​
FDA Updates Emergency Use Authorization for Monoclonal Antibody Cocktail - Casirivimab and Imdevima
​The U.S. Food and Drug Administration (FDA) has updated the Emergency Use Authorization (EUA) for REGEN-COV™, adding an alternative route of administration (subcutaneous) and lowering the dose to 1,200 mg (600 mg casirivimab and 600 mg imdevimab), which is half the dose originally authorized. The EUA provides that casirivimab and imdevimab are to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19 and/or hospitalization.

Additional Resources
  • Important Prescribing Information Regarding REGEN-COV™ (casirivimab and imdevimab)
  • Fact Sheet for Health Care Providers Regarding EUA of REGEN-COV™ (casirivimab and imdevimab)
  • Information Regarding Monoclonal Antibodies for High-Risk COVID-19 Positive Patients
  • Monoclonal Antibody Resources for Clinicians

Florida Hospital Association.  All Rights Reserved.
306 East College Avenue | Tallahassee, FL 32301
Phone: (850) 222-9800 | Email: Communications@FHA.org | sitemap